Cardiovascular Drug Interactions With Nirmatrelvir/Ritonavir in Patients With COVID-19: JACC Review Topic of the Week

Nirmatrelvir-ritonavir (NMVr) is used to treat symptomatic, nonhospitalized patients with coronavirus disease-2019 (COVID-19) who are at high risk of progression to severe disease. Patients with cardiovascular risk factors and cardiovascular disease are at a high risk of developing adverse events fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Abraham, Sonu, Nohria, Anju, Neilan, Tomas G., Asnani, Aarti, Saji, Anu Mariam, Shah, Jui, Lech, Tara, Grossman, Jason, Abraham, George M., McQuillen, Daniel P., Martin, David T., Sax, Paul E., Dani, Sourbha S., Ganatra, Sarju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: by the American College of Cardiology Foundation. Published by Elsevier. 2022
Materias:
The Present and Future
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580069/
https://www.ncbi.nlm.nih.gov/pubmed/36243540
http://dx.doi.org/10.1016/j.jacc.2022.08.800

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580069/
https://www.ncbi.nlm.nih.gov/pubmed/36243540
http://dx.doi.org/10.1016/j.jacc.2022.08.800

Ejemplares similares